Walleye Capital
BMRN icon

Walleye Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Walleye Capital’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.5M Sell
288,233
-76,013
-21% -$4.16M 0.06% 296
2026
Q1 		$20.6M Buy
364,246
+141,779
+64% +$8.27M 0.09% 188
2025
Q4 		$13.2M Buy
222,467
+150,655
+210% +$8.2M 0.04% 479
2025
Q3 		$3.89M Buy
71,812
+71,746
+108,706% +$4.1M 0.01% 1089
2025
Q2 		$3.63K Sell
66
-32,705
-100% -$1.93M ﹤0.01% 4367
2025
Q1 		$2.32M Buy
32,771
+4,699
+17% +$316K 0.01% 1311
2024
Q4 		$1.85M Sell
28,072
-127,370
-82% -$8.53M ﹤0.01% 1855
2024
Q3 		$10.9M Buy
155,442
+117,119
+306% +$9.79M 0.02% 640
2024
Q2 		$3.16M Buy
38,323
+3,639
+10% +$303K 0.01% 1683
2024
Q1 		$3.03M Buy
34,684
+22,111
+176% +$1.98M 0.01% 1687
2023
Q4 		$1.21M Buy
12,573
+7,572
+151% +$670K ﹤0.01% 2194
2023
Q3 		$442K Sell
5,001
-43,638
-90% -$3.88M ﹤0.01% 2907
2023
Q2 		$4.22M Sell
48,639
-88,633
-65% -$8.34M 0.02% 843
2023
Q1 		$13.3M Buy
137,272
+71,798
+110% +$7.44M 0.2% 97
2022
Q4 		$6.78M Sell
65,474
-27,272
-29% -$2.56M 0.12% 205
2022
Q3 		$7.86M Buy
92,746
+52,496
+130% +$4.67M 0.15% 147
2022
Q2 		$3.34M Sell
40,250
-75,399
-65% -$6M 0.09% 243
2022
Q1 		$8.92M Buy
115,649
+104,154
+906% +$8.71M 0.24% 87
2021
Q4 		$1.02M Buy
+11,495
New +$949K 0.03% 584
2021
Q3 		– Sell
-3,560
Closed -$297K – 1601
2021
Q2 		$297K Buy
+3,560
New +$282K 0.01% 944
2019
Q2 		– Sell
-822
Closed -$70.3K – 1739
2019
Q1 		$73K Buy
+822
New +$76.2K 0.01% 1116

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Walleye Capital's BMRN Position: Q2 2026 in Review

Walleye Capital reduced its BioMarin Pharmaceuticals (BMRN) stake by 21% in Q2 2026, selling an estimated $4.16M and leaving 288,233 shares worth $16.5M. The position accounts for 0.06% of the portfolio, ranked #296.

Walleye Capital first reported a position in BMRN in Q1 2019 and has held it in 21 quarters since. The position peaked at $20.6M in Q1 2026. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Walleye Capital held 288,233 shares of BioMarin Pharmaceuticals worth $16.5M as of Q2 2026.
  • Walleye Capital sold 76,013 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $4.16M.
  • BioMarin Pharmaceuticals made up 0.06% of Walleye Capital's portfolio in Q2 2026, its #296 holding.
  • Walleye Capital first reported a position in BioMarin Pharmaceuticals in Q1 2019 and has held it in 21 quarters since.
  • Walleye Capital's BioMarin Pharmaceuticals position peaked at $20.6M in Q1 2026.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.